REGN clearly states in their filing that the competition is fierce and they are happy to steal any and all information to make a couple billion now and worry about settling in court for a few million later. They have a history of this.
Recent REGN News
- Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss • GlobeNewswire Inc. • 05/22/2026 11:00:00 AM
- Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis • GlobeNewswire Inc. • 05/21/2026 09:01:52 PM
- Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas • GlobeNewswire Inc. • 05/18/2026 11:00:00 AM
- Regeneron slides after melanoma study misses key endpoint (REGN) • IH Market News • 05/18/2026 10:19:25 AM
- Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma • GlobeNewswire Inc. • 05/16/2026 12:19:44 AM
- UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair • GlobeNewswire Inc. • 05/15/2026 09:56:33 PM
- Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair • GlobeNewswire Inc. • 05/15/2026 08:27:38 PM
- Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair • GlobeNewswire Inc. • 05/15/2026 06:09:52 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/08/2026 08:09:13 PM
- Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years • GlobeNewswire Inc. • 05/08/2026 11:00:00 AM
- Biotech’s Next Wave May Already be in Motion • GlobeNewswire Inc. • 05/07/2026 12:45:00 PM
- Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE • IH Market News • 05/05/2026 02:14:08 PM
- Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Regeneron Tops Q1 Estimates on Dupixent Momentum • IH Market News • 04/29/2026 12:53:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 10:54:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 10:50:22 AM
- Regeneron Reports First Quarter 2026 Financial and Operating Results • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Markets Steady Ahead of Fed Decision and Key Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • IH Market News • 04/29/2026 09:16:13 AM
- Markets Hold Steady Ahead of Fed Call and Big Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • UK Market News • 04/29/2026 09:15:43 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:04:21 PM
- Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. • GlobeNewswire Inc. • 04/23/2026 07:46:16 PM
- Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. • GlobeNewswire Inc. • 04/23/2026 04:40:00 PM
- Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 04/22/2026 09:30:00 PM
